Showing results (231-240 of 757) with videos related to

Sort By:
Pageof 76
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studiesAmy Y Xiao, Marianne L Y Tan, Landy M Wu, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Pathogenesis and novel treatment options for non-alcoholic steatohepatitisVincent Wai-Sun Wong, Shiv Chitturi, Grace Lai-Hung Wong, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility studyNiels J Harlaar, Marjory Koller, Steven J de Jongh, et al.
The Lancet. Gastroenterology & Hepatology|March 25, 2021
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysisMichelle Bosman, Sigrid Elsenbruch, Maura Corsetti, et al.
The Lancet. Gastroenterology & Hepatology|March 9, 2025
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort studyKavish R Patidar, Ann T Ma, Adrià Juanola, et al.
The Lancet. Gastroenterology & Hepatology|December 14, 2024
Rome Foundation and international neurogastroenterology and motility societies' consensus on idiopathic gastroparesisJolien Schol, I-Hsuan Huang, Florencia Carbone, et al.
The Lancet. Gastroenterology & Hepatology|December 12, 2024
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trialGuillaume Martel, François Martin Carrier, Christopher Wherrett, et al.
The Lancet. Gastroenterology & Hepatology|November 21, 2024
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trialGeert D'Haens, Carlos Taxonera, Antonio Lopez-Sanroman, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2024
Personalisation of therapy in irritable bowel syndrome: a hypothesisChristopher J Black, Alexander C Ford
The Lancet. Gastroenterology & Hepatology|October 10, 2024
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 studyMan-Fung Yuen, Young-Suk Lim, Ki Tae Yoon, et al.
Pageof 76